https://www.selleckchem.com/pr....oducts/Cediranib.htm
Allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen (HLA)-matched related donor is an effective treatment option for sever aplastic anemia (SAA). HSCT from an unrelated donor has also been reported. Engraftment failure and graft-versus-host disease (GVHD) are major obstacles in HSCT for SAA, and the combination of high-dose cyclophosphamide (CY) and anti-thymocyte globulin (ATG) has been utilized as a conditioning regimen for overcoming these obstacles. However, cardiac toxicity due to high-dose CY
Like
Comment
Share
